FDA approves first broad RAS-targeted pill Rasonque for metastatic pancreatic cancer

By Peace Longe Sat, August 29, 2026 at 10:07 AM PDT | 5 min read

For decades, a pancreatic cancer diagnosis came with almost no good options. The disease is usually caught late, spreads fast, and resists most treatments. Patients and their families were often left with months, not years.

That grim picture just changed.

On Aug. 26, the U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a once-daily pill from Revolution Medicines (RVMD) .

It is the first broad RAS-targeted medicine cleared for adults with metastatic pancreatic cancer who have already received chemotherapy.

For investors, the approval turns a research-stage company into one with a product on pharmacy shelves. The stock reaction, though, was quieter than you might expect.

What Revolution Medicines' Rasonque Does That Older Drugs Could Not

Most pancreatic tumors are driven by a mutated protein called RAS. When RAS goes wrong, it tells cancer cells to keep growing.

RAS mutations appear in over 90% of pancreatic cancer cases, making the protein one of the most important targets in cancer research, according to NPR.

It was also one of the hardest to hit, and drugmakers spent years trying and failing.

More Healthcare Stocks:

• Merck adds $43 billion after cancer vaccine trial win
• BofA biotech scorecard: Two buys and one odd one out
• Federal court hands Gilead a win that protects its top HIV drug

Rasonque attacks several forms of mutated RAS directly. The results were striking.

In the RASolute 302 Phase 3 trial of 500 previously treated patients, the drug nearly doubled median overall survival to 13.2 months, up from 6.7 months on standard chemotherapy, according to the FDA.

It also cut the risk of death by 60%.

The drug is not a cure, and doctors are clear about that. It buys patients more time, which for this cancer is a meaningful shift.

Why the FDA Cleared the Pancreatic Cancer Drug So Fast

The speed of this approval stood out almost as much as the data.

The FDA cleared Rasonque about five weeks, or 35 days, after accepting the application, BioPharma Dive reported. A typical review runs 10 to 12 months.

Revolution moved through the FDA's Commissioner's National Priority Voucher program, which fast-tracks drugs that address major public health needs.

The drug also carried Breakthrough Therapy and Orphan Drug designations.

Before full approval, more than 2,000 patients had already received the drug through an expanded access program, Reuters confirmed.

That head start matters for revenue, because those patients form a ready base of early demand.

The FDA's approval of Rasonque gives adults with previously treated metastatic pancreatic cancer the first broad RAS-targeted pill, nearly doubling median survival in its trial. (Win McNamee / Getty Images)

How the Approval Reshapes RVMD's Business

Until this week, Revolution Medicines earned no product revenue.

It was a clinical-stage company living off its balance sheet, which held $3.9 billion in cash as of June 30, according to MedCity News.

Now it has a commercial drug and a price tag to match. Revolution set the wholesale cost at $39,800 for a 30-day supply, CNN reported.

Some commercially insured patients could pay as little as $0 through co-pay assistance.

Analysts at RBC Capital Markets laid out how sales could ramp.

RBC's Early Sales Forecast for Rasonque

• Third quarter 2026: About $28 million in U.S. revenue
• Fourth quarter 2026: Roughly $148 million
• Peak annual sales: An estimated $11.5 billion over the long term

Those figures explain why investors were watching this approval closely.